Physician profile
Ashraf A Iskander
NPI 1437167541
$3,594.39
in general payments reported to CMS, 2019-2025
24 companies · $637 in 2025
The $637 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $183 · 2021: $561 · 2022: $335 · 2023: $984 · 2024: $513 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,134.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $885.55 | 2019-2025 | Grafix, Oasis, Stravix Pl |
| Organogenesis INC. | $757.47 | 2019-2025 | Puraply, Apligraf |
| Lilly USA, LLC | $471.40 | 2023-2025 | Mounjaro |
| Kerecis Limited | $377.32 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Aroa Biosurgery Incorporated | $136.04 | 2022 | |
| Misonix INC | $115.64 | 2020 | |
| Hydrofera LLC | $95.00 | 2021 | |
| Mimedx Group, INC. | $92.26 | 2025 | |
| Janssen Pharmaceuticals, INC | $80.46 | 2019 | |
| Abbott Laboratories | $68.44 | 2022-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $66.67 | 2024-2025 | Airsupra, Breztri |
| Pfizer INC. | $65.48 | 2021-2025 | |
| Novo Nordisk INC | $60.73 | 2023-2024 | Rybelsus, Ozempic |
| Kowa Pharmaceuticals America, INC. | $55.90 | 2023-2024 | Livalo, Seglentis |
| Abbvie INC. | $48.62 | 2024-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $40.80 | 2019 | |
| Merck Sharp & Dohme LLC | $33.16 | 2023 | Verquvo, Belsomra |
| Astellas Pharma US INC | $26.35 | 2025 | Veozah |
| Allergan, INC. | $23.14 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.41 | 2025 | Rexulti |
| Paratek Pharmaceuticals, INC. | $19.96 | 2024 | Nuzyra |
| Dexcom, INC. | $18.52 | 2023 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $18.31 | 2024 | Trelegy Ellipta |
| Xeris Pharmaceuticals, INC. | $15.76 | 2025 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashraf Iskander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.